Sanofi $SNY Shares Sold by Dodge & Cox

Key Points

• Dodge & Cox has reduced its holdings in Sanofi by 2.7% during the first quarter, making it the 9th largest position in their portfolio, with current ownership of approximately $4.06 billion.
• Several brokerages have rated Sanofi with a consensus "Buy" rating and set a price target averaging $62.00, indicating positive market sentiment around the stock.
• Sanofi's latest earnings report showed an EPS of $0.90, falling short of the estimated $0.96, despite having revenues exceeding expectations at $11.34 billion.

Dodge & Cox trimmed its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 2.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 73,193,057 shares of the company's stock after selling 2,027,531 shares during the period. Sanofi accounts for 2.3% of Dodge & Cox's holdings, making the stock its 9th biggest position. Dodge & Cox owned about 2.90% of Sanofi worth $4,059,287,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Accent Capital Management LLC purchased a new position in Sanofi during the first quarter valued at $29,000. Eastern Bank lifted its holdings in Sanofi by 121.0% during the first quarter. Eastern Bank now owns 548 shares of the company's stock valued at $30,000 after purchasing an additional 300 shares in the last quarter. Golden State Wealth Management LLC lifted its holdings in Sanofi by 619.3% during the first quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock valued at $35,000 after purchasing an additional 545 shares in the last quarter. Brentview Investment Management LLC purchased a new position in Sanofi during the first quarter valued at $42,000. Finally, UMB Bank n.a. lifted its holdings in Sanofi by 30.7% during the first quarter. UMB Bank n.a. now owns 1,124 shares of the company's stock valued at $62,000 after purchasing an additional 264 shares in the last quarter. 14.04% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on SNY shares. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Sanofi in a research note on Tuesday, August 5th. Wall Street Zen raised shares of Sanofi from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Guggenheim reissued a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. Morgan Stanley set a $56.00 price target on shares of Sanofi in a research note on Monday, June 2nd. Finally, JPMorgan Chase & Co. raised shares of Sanofi from a "neutral" rating to an "overweight" rating in a research note on Friday, August 8th. Three analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $62.00.

Sanofi Trading Down 0.4%

Sanofi stock traded down $0.19 during midday trading on Wednesday, hitting $50.11. 2,044,486 shares of the stock were exchanged, compared to its average volume of 2,544,232. Sanofi has a fifty-two week low of $44.73 and a fifty-two week high of $60.12. The stock has a market capitalization of $123.05 billion, a price-to-earnings ratio of 12.05, a PEG ratio of 1.19 and a beta of 0.48. The stock's 50-day simple moving average is $48.68 and its 200 day simple moving average is $51.67. The company has a current ratio of 1.27, a quick ratio of 0.94 and a debt-to-equity ratio of 0.19.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.96 by ($0.06). Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The firm had revenue of $11.34 billion for the quarter, compared to analyst estimates of $9.91 billion. During the same quarter in the previous year, the business posted $1.73 earnings per share. Sanofi's revenue for the quarter was down 7.0% on a year-over-year basis. On average, equities analysts anticipate that Sanofi will post 4.36 EPS for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.